<DOC>
	<DOCNO>NCT01465763</DOCNO>
	<brief_summary>This study design evaluate efficacy safety tofacitinib ( CP-690,550 ) patient moderate severe ulcerative colitis fail intolerant one follow treatment ulcerative colitis : oral steroid , azathiopurine/6-mercaptopurine , anti-TNF-alpha therapy .</brief_summary>
	<brief_title>A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Subject must least 18 year age . Males female document diagnosis UC least 4 month prior entry study . Subjects moderately severely active UC base Mayo score criterion . Subjects must fail intolerant least one follow treatment UC : Corticosteroids ( oral intravenous ) . Azathioprine 6 mercaptopurine ( 6 MP ) . Anti TNFalpha therapy . Presence indeterminate colitis , microscopic colitis , ischemic colitis , infectious colitis , clinical finding suggestive Crohn 's disease . Subjects disease limit distal 15 cm . Subjects without previous treatment UC ( ie , treatment na√Øve ) . Subjects display clinical sign fulminant colitis toxic megacolon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Moderate severe ulcerative colitis</keyword>
	<keyword>phase 3 clinical trial</keyword>
	<keyword>Mayo score</keyword>
</DOC>